Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Agilent Technologies, Inc. (A) — XLV Health Care · S&P 500 Profile |安捷倫公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Agilent Technologies, Inc. (A) — Business, History & S&P 500 Profile | 安捷倫公司介紹

Agilent Technologies, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #233 · 安捷倫公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (ET) close
Financials: FY2025
MARKET CAP
$49.30B
Oct 30, 2026 close
S&P 500 WEIGHT
0.07%
Rank #233 · Oct 30, 2026
SECTOR RANK
#31
Health Care · Oct 30, 2026
S&P 500 RANK
#233
0.07% · Oct 30, 2026

SNAPSHOT

TickerA
CompanyAgilent Technologies, Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#233 · 0.07% (Oct 30, 2026)
Sector rank#31 in Health Care (Oct 30, 2026)
HeadquartersSanta Clara, California
Founded1999
CEOPadraig McDonnell (CEO)
Employees18,100 (2025)
Market cap$49.30B (Oct 30, 2026)
Share price$174.87 (Oct 30, 2026)
SEC filingsEDGAR — CIK 0001090872

WHAT IT DOES

Agilent Technologies, Inc. is a laboratory-technology company headquartered in Santa Clara, California, providing instruments, software, services and consumables for laboratories in life sciences, diagnostics and applied markets. It was established in 1999 as a spin-off from Hewlett-Packard.

Its one-line model: sell the analytical platforms a laboratory runs on — chromatography, mass spectrometry, spectroscopy, genomics and cell analysis — then earn recurring revenue from the services, consumables and software attached to that installed base through its CrossLab arm.

The economics are installed-base economics: instruments are cyclical capital purchases, but CrossLab was the largest fiscal 2025 segment at $2.91B of $6.95B revenue and the highest-margin one (segment income $946M, a 32.5% segment margin), which steadies the cycle. Fiscal 2025 revenue grew 6.7% to $6.95B (year ended October 31, 2025).

BUSINESS SEGMENTS

Agilent CrossLabServices, consumables, software, automation and lab-productivity solutions across vendors' instruments — fiscal 2025 segment revenue of $2.91B, Agilent's largest segment, with segment income of $946M.
Life Sciences and Diagnostics Markets — Life SciencesInstruments and workflows for pharma, biotech, academia and government research, including chromatography, mass spectrometry and cell analysis; together with Diagnostics below, the segment reported fiscal 2025 revenue of $2.73B and segment income of $536M.
Life Sciences and Diagnostics Markets — Diagnostics & GenomicsCancer diagnostics and pathology (Dako), genomics and target enrichment, and nucleic-acid therapeutics manufacturing (the Frederick, Colorado expansion) within the same reportable segment as Life Sciences above.
Applied MarketsGas chromatography, spectroscopy, vacuum and remarketed instruments for food, environmental, chemicals, energy, semiconductor, battery and forensic customers — fiscal 2025 segment revenue of $1.31B, with segment income of $301M.

Agilent CrossLab Services, consumables, software, automation and lab-productivity solutions across vendors' instruments — fiscal 2025 segment revenue of $2.91B, Agilent's largest segment, with segment income of $946M.

Life Sciences and Diagnostics Markets — Life Sciences Instruments and workflows for pharma, biotech, academia and government research, including chromatography, mass spectrometry and cell analysis; together with Diagnostics below, the segment reported fiscal 2025 revenue of $2.73B and segment income of $536M.

Life Sciences and Diagnostics Markets — Diagnostics & Genomics Cancer diagnostics and pathology (Dako), genomics and target enrichment, and nucleic-acid therapeutics manufacturing (the Frederick, Colorado expansion) within the same reportable segment as Life Sciences above.

Applied Markets Gas chromatography, spectroscopy, vacuum and remarketed instruments for food, environmental, chemicals, energy, semiconductor, battery and forensic customers — fiscal 2025 segment revenue of $1.31B, with segment income of $301M.

HISTORY

YearMilestone
1999Agilent is created in 1999 as a spin-off of Hewlett-Packard's test & measurement, instrumentation, chemical-analysis and related units; its IPO raises $2.1 billion, the largest in Silicon Valley history at the time.
2005Agilent sells its semiconductor products business to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion in August 2005; the business later becomes Avago (today Broadcom).
2012Agilent agrees to buy Danish cancer-diagnostics company Dako for $2.2 billion in May 2012, its decisive move into clinical diagnostics.
2014The separation of Agilent and its electronic-measurement spin-off Keysight Technologies completes on November 1, 2014, leaving Agilent as the life-sciences, diagnostics and applied-markets company it is today.
2019Agilent acquires BioTek Instruments, a life-science instrumentation maker, for $1.165 billion in August 2019.
2024Padraig McDonnell, formerly president of the CrossLab Group and chief commercial officer, succeeds Mike McMullen as CEO on May 1, 2024.

COMPETITIVE POSITION

  • Installed base plus services: CrossLab monetises laboratories regardless of instrument brand, producing the group's highest segment margin (32.5% in fiscal 2025) and 53% of reportable segment income on 42% of revenue.
  • Analytical breadth: chromatography, mass spectrometry, spectroscopy, genomics and cell analysis under one vendor, with informatics (OpenLab) tying workflows together.
  • Diagnostics position: the Dako pathology franchise gives Agilent a regulated clinical revenue line most instrument rivals lack.
  • Competition set: Thermo Fisher Scientific, Danaher, Waters, Shimadzu and PerkinElmer/Revvity across instruments, services and diagnostics.

FINANCIAL SNAPSHOT

Net revenue$6.95B (FY2025 revenue)
Income from operations$1.48B (FY2025 operating income)
Net income$1.30B (FY2025 net income)
Diluted EPS$4.57 (FY2025 diluted EPS)
Source: Agilent fiscal 2025 results release (November 24, 2025) and fiscal 2025 Form 10-K (year ended October 31, 2025) — revenue $6,948M, income from operations $1,479M, GAAP net income $1,303M, diluted EPS $4.57; non-GAAP net income was $1,592M (EPS $5.59). Segment revenue and segment income via the fiscal 2025 release / StockAnalysis segment reporting under the fiscal 2025 reorganised structure (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets); the three segments sum to total revenue. Agilent's fiscal year ends October 31.

KEY RISKS

  • Laboratory capital-spending cycles: instrument demand follows pharma and biotech funding, which contracted after the pandemic inventory build.
  • China exposure: a material share of applied and life-sciences demand is China-linked and exposed to trade and stimulus swings.
  • Segment-mix shift: the fiscal 2025 reorganisation and CDMO build-out (Frederick expansion) change the margin profile investors modelled under the old structure.
  • Regulatory and reimbursement pressure on diagnostics customers, including U.S. laboratory-developed-test rules.
  • Currency and tariff costs across a global manufacturing and sales base.

WHY IT MATTERS FOR THE S&P 500

Agilent is a small-weight health-care constituent: rank #233 by weight at 0.07% as of Oct 30, 2026, and #31 in Health Care. As the index's laboratory-instrument pure play with a services arm larger than any product segment, it is a direct read on global research and diagnostics spending — and on how installed-base services smooth an instrument cycle.

SOURCES & METHODOLOGY

Financials, segments, headquartersAgilent fiscal 2025 results release and Form 10-K data via company release, Wikipedia company profile and StockAnalysis (year ended October 31, 2025); headquarters, CEO and employees via Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, Oct 30, 2026 close, fetched Nov 2, 2026 (dispatch baseline, used verbatim)
Market cap$49.30B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

A

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號A
公司Agilent Technologies, Inc.(安捷倫)
GICS 板塊/行業醫療保健(XLV)/生命科學工具及服務
標普500排名(按權重)#233 · 0.07%(Oct 30, 2026)
板塊內排名醫療保健 #31(Oct 30, 2026)
總部美國加利福尼亞州聖克拉拉
成立1999年
執行長Padraig McDonnell(執行長)
員工18,100(2025年)
市值$49.30B(Oct 30, 2026)
股價$174.87(Oct 30, 2026)
SEC 申報EDGAR — CIK 0001090872

業務概覽

安捷倫是一家總部位於加利福尼亞州聖克拉拉的實驗室科技公司,為生命科學、診斷與應用市場的實驗室提供儀器、軟件、服務與耗材。它於 1999 年由惠普分拆成立。

其一句話商業模式是:銷售實驗室運作所依賴的分析平台——色譜、質譜、光譜、基因組學與細胞分析——再透過其 CrossLab 部門,從該裝機基礎附帶的服務、耗材與軟件賺取經常性收入。

其經濟學是裝機基礎經濟學:儀器屬週期性的資本購買,但 CrossLab 是 2025 財年最大板塊(收入 29.1 億美元,總收入為 69.5 億美元),且利潤率最高(板塊利潤 9.46 億美元,板塊利潤率 32.5%),因而平滑週期。2025 財年收入增長 6.7% 至 69.5 億美元(截至 2025 年 10 月 31 日)。

業務板塊

Agilent CrossLab跨品牌儀器的服務、耗材、軟件、自動化與實驗室生產力解決方案——2025 財年板塊收入 29.1 億美元,為安捷倫最大板塊,板塊利潤 9.46 億美元。
生命科學與診斷市場 — 生命科學供製藥、生物科技、學術與政府研究的儀器與工作流程,包括色譜、質譜與細胞分析;與下文診斷業務同屬一個可報告板塊,該板塊 2025 財年收入 27.3 億美元,板塊利潤 5.36 億美元。
生命科學與診斷市場 — 診斷與基因組學癌症診斷與病理(Dako)、基因組學與目標富集,以及核酸療法生產(科羅拉多州 Frederick 擴建),與上文生命科學同屬一個可報告板塊。
應用市場供食品、環境、化工、能源、半導體、電池與法證客戶的氣相色譜、光譜、真空與再銷售儀器——2025 財年板塊收入 13.1 億美元,板塊利潤 3.01 億美元。

Agilent CrossLab 跨品牌儀器的服務、耗材、軟件、自動化與實驗室生產力解決方案——2025 財年板塊收入 29.1 億美元,為安捷倫最大板塊,板塊利潤 9.46 億美元。

生命科學與診斷市場 — 生命科學 供製藥、生物科技、學術與政府研究的儀器與工作流程,包括色譜、質譜與細胞分析;與下文診斷業務同屬一個可報告板塊,該板塊 2025 財年收入 27.3 億美元,板塊利潤 5.36 億美元。

生命科學與診斷市場 — 診斷與基因組學 癌症診斷與病理(Dako)、基因組學與目標富集,以及核酸療法生產(科羅拉多州 Frederick 擴建),與上文生命科學同屬一個可報告板塊。

應用市場 供食品、環境、化工、能源、半導體、電池與法證客戶的氣相色譜、光譜、真空與再銷售儀器——2025 財年板塊收入 13.1 億美元,板塊利潤 3.01 億美元。

歷史沿革

年份里程碑
1999安捷倫於 1999 年由惠普的測試與量測、儀器、化學分析及相關部門分拆成立;其 IPO 籌集 21 億美元,為當時矽谷史上最大。
2005安捷倫於 2005 年 8 月以 26.6 億美元把半導體產品業務售予 Kohlberg Kravis Roberts 與 Silver Lake Partners;該業務其後成為 Avago(今日的 Broadcom)。
2012安捷倫於 2012 年 5 月同意以 22 億美元收購丹麥癌症診斷公司 Dako,是其進軍臨床診斷的決定性一步。
2014安捷倫與其電子量測分拆公司 Keysight Technologies 的分離於 2014 年 11 月 1 日完成,安捷倫自此成為今日的生命科學、診斷與應用市場公司。
2019安捷倫於 2019 年 8 月以 11.65 億美元收購生命科學儀器製造商 BioTek Instruments。
2024前 CrossLab 集團總裁兼首席商務官 Padraig McDonnell 於 2024 年 5 月 1 日接替 Mike McMullen 出任執行長。

競爭地位

  • 裝機基礎加服務:CrossLab 不分儀器品牌地把實驗室變現,取得集團最高的板塊利潤率(2025 財年 32.5%),以 42% 的收入貢獻 53% 的可報告板塊利潤。
  • 分析廣度:色譜、質譜、光譜、基因組學與細胞分析集於一家供應商,並由資訊系統(OpenLab)把工作流程串連。
  • 診斷地位:Dako 病理業務線令安捷倫擁有一條多數儀器對手所缺乏的受監管臨床收入線。
  • 競爭集合:儀器、服務與診斷領域的 Thermo Fisher Scientific、Danaher、Waters、Shimadzu 與 PerkinElmer/Revvity。

財務快照

淨收入$6.95B(FY2025 收入)
營業利潤$1.48B(FY2025 營業利潤)
淨利潤$1.30B(FY2025 淨利潤)
稀釋 EPS$4.57(FY2025 稀釋 EPS)
來源:安捷倫 2025 財年業績公告(2025 年 11 月 24 日)及 2025 財年 Form 10-K(截至 2025 年 10 月 31 日)——收入 69.48 億美元、營業利潤 14.79 億美元、GAAP 淨利潤 13.03 億美元、稀釋 EPS 4.57 美元;非 GAAP 淨利潤為 15.92 億美元(EPS 5.59 美元)。板塊收入與板塊利潤經 2025 財年公告/StockAnalysis 板塊報道,按 2025 財年重組後架構(生命科學與診斷市場、Agilent CrossLab、應用市場)列示;三個板塊合計為總收入。安捷倫財年於 10 月 31 日結束。

主要風險

  • 實驗室資本支出週期:儀器需求跟隨製藥與生物科技資金,疫情後庫存積壓後曾收縮。
  • 中國曝險:應用與生命科學需求中有相當部分與中國相關,曝露於貿易與刺激政策的波動。
  • 板塊組合轉變:2025 財年重組與 CDMO 擴建(Frederick 擴建)改變了投資者按舊架構所建模的利潤率輪廓。
  • 診斷客戶面對的監管與報銷壓力,包括美國實驗室自建檢測規則。
  • 全球製造與銷售基礎帶來的匯率與關稅成本。

對標普500的重要性

安捷倫是權重較小的醫療保健成分股:按權重排名 #233,權重 0.07%(以 Oct 30, 2026 為準),醫療保健板塊內排名 #31。作為指數中服務部門大於任何產品板塊的實驗室儀器純粹企業,它是觀察全球研究與診斷支出的直接指標,也顯示裝機基礎服務如何平滑儀器週期。

來源與方法

財務、板塊、總部安捷倫 2025 財年業績公告與 Form 10-K 數據,經公司公告、維基百科公司資料與 StockAnalysis(截至 2025 年 10 月 31 日);總部、執行長與員工經維基百科公司資料
指數權重與排名Slickcharts S&P 500 權重,Oct 30, 2026 收盤,Nov 2, 2026 抓取(派工基線,原文引用)
市值$49.30B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

A

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · A
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Ford Motor Company (F) — XLY Consumer Discretionary · S&P 500 Profile |福特公司介紹Next · Humana Inc. (HUM) — XLV Health Care · S&P 500 Profile |Humana公司介紹

Entered 2026-11-01 19:29 · updated 2026-11-14 22:48 · rev 5